Lucira up on filing for authorization of over-the-counter use of COVID, flu test

Lucira Health

03/01/2023 13:23

** Shares of medical test maker Lucira Health Inc  LHDX.O 
rise 34.5% to $0.15 premarket
    ** LHDX submits emergency use authorization application to
the U.S. Food and Drug Administration (FDA) for over-the-counter
use of its molecular COVID-19 and flu test, which was granted
point-of-care use authorization last November    
    ** Says it worked with the FDA to complete additional
testing to demonstrate that the test can be used at home
    ** LHDX shares fell 98.71% last year
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))